Baseline characteristics of the patients
| Characteristics | Placebo | Infliximab 5 mg/kg |
|---|---|---|
| *Values are means (SD). | ||
| ACR, American College of Rheumatology; BSA, body surface area; CRP, C reactive protein; DIP, distal interphalangeal; HAQ, Health Assessment Questionnaire; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; SF-36, Short Form-36; VAS, visual analogue scale. | ||
| Patients randomised (n) | 100 | 100 |
| Female sex (%) | 49.0 | 29.0 |
| Age (years)* | 46.5 (11.3) | 47.1 (12.8) |
| Weight (kg)* | 84.5 (20.3) | 87.9 (16.5) |
| PsA subtype (%) | ||
| Arthritis involving DIPs | 23.0 | 26.0 |
| Arthritis mutilans | 2.0 | 1.0 |
| Asymmetric peripheral arthritis | 22.0 | 18.0 |
| Polyarticular arthritis | 47.0 | 53.0 |
| Spondylitis with peripheral arthritis | 6.0 | 2.0 |
| PsA duration (years)* | 7.5 (7.8) | 8.4 (7.2) |
| ACR component* | ||
| Number of swollen joints (0–66) | 14.4 (8.9) | 13.9 (7.9) |
| Number of tender joints (0–68) | 25.1 (13.3) | 24.6 (14.1) |
| CRP (mg/l) | 23 (34) | 19 (21) |
| Physician’s global assessment of disease activity (VAS; 0–10 cm) | 5.9 (1.7) | 5.5 (1.8) |
| Patient’s global assessment of disease activity (VAS; 0–10 cm) | 5.9 (2.2) | 5.4 (2.1) |
| Patient’s assessment of pain (VAS; 0–10 cm) | 5.9 (2.3) | 5.6 (2.1) |
| HAQ disability index (0–3) | 1.1 (0.6) | 1.1 (0.6) |
| Duration of morning stiffness (0–1440 min)* | 183.4 (308.8) | 216.0 (376.0) |
| Patients with one or more digits with dactylitis (%) | 41.0 | 40.0 |
| Patients with enthesopathy (%) | 35.0 | 42.0 |
| Psoriasis duration (years)* | 16.8 (12.0) | 16.2 (11.0) |
| Psoriasis evaluation | ||
| Patients with ⩾3% BSA with psoriasis (%) | 87.0 | 83.0 |
| PASI score (0–72)* | 10.2 (9.0) | 11.4 (12.7) |
| Patients with PASI ⩾10 | 31.0 | 30.0 |
| Target lesion score (0–12)* | 6.2 (1.9) | 5.9 (2.2) |
| SF-36 score* | ||
| Physical component (0–100) | 31.0 (9.0) | 33.0 (9.4) |
| Mental component (0–100) | 47.0 (11.9) | 45.5 (11.9) |
| Baseline drug | ||
| Patients taking MTX (%) | 45.0 | 47.0 |
| MTX dose (mg/week)* | 14.8 (5.4) | 16.2 (5.2) |
| Patients taking oral corticosteroids (%) | 10.0 | 15.0 |
| Patients taking NSAIDs (%) | 73.0 | 71.0 |